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Background. One of the major challenges affecting sarcoma treatment outcome, particularly that of metastatic disease, is resistance
to chemotherapy. Cancer-initiating cells are considered a major contributor to this resistance. Methods. An immortalised
nontransformed human stromal (mesenchymal) stem cell line hMSC-TERT4 and a transformed cell line hMSC-TERT20-CE8,
known to form sarcoma-like tumours when implanted in immune-deficient mice, were used as models. Receptor tyrosine kinase
(RTK) activation was analysed by RTK arrays and cellular viability after tyrosine kinases inhibitor (TKI) treatment with or without
doxorubicin was assessed by MTS assay. Results. Initial results showed that the hMSC-TERT4 was more doxorubicin-sensitive
while hMSC-TERT20-CE8 was less doxorubicin-sensitive evidenced by monitoring cell viability in the presence of doxorubicin
at different doses. The epidermal growth factor receptor (EGFR) was activated in both cell lines. However hMSC-TERT20-
CE8 exhibited significantly higher expression of the EGFR ligands. EGFR inhibitors such as erlotinib and afatinib alone or in
combination with doxorubicin failed to further decrease cell viability of hMSC-TERT20-CE8. However, inhibition with the TKI
dasatinib in combination with doxorubicin decreased cell viability of the hMSC-TERT20-CE8 cell line. Conclusion. Our results
demonstrate that dasatinib, but not EGFR-directed treatment, can decrease cell viability of stromal cancer stem cells less sensitive
to doxorubicin.
1. Background
Sarcomas are suggested to develop from stromal (also known
as mesenchymal) stem cells with acquired genetic mutations
leading to cellular transformation [1, 2]. It is generally
believed that the poor clinical outcome is directly related
to chemotherapy-resistant cancer-initiating stem cells. The
standard first line treatment of patients with metastatic
soft tissue sarcoma (STS) is doxorubicin. However, most
metastatic sarcomas have intrinsic resistance or will acquire
resistance to doxorubicin. Unfortunately, no significant
changes have occurred during the past 20 years regarding
treatment options available for patients with metastatic STS
[3] and the median overall survival for these patients contin-
ues to be around 2 years [4].
Activation of critical survival pathways in stromal cancer-
initiating cells through receptor tyrosine kinases (RTKs) sig-
naling contributes to chemotherapy-resistance in sarcomas as
RTKs signaling is important for maintenance of cell survival
[5].
Combining chemotherapy with RTK-targeted treatment
presents an advantage for targeting cellular resistance against
doxorubicin. This approach has been successful in over-
coming tumour cell resistance to doxorubicin in small cell
sarcoma cell lines [6]. In spite of this initial success, it is still
unclear which RTKs to target and if a combined treatment
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modality is effective. Few models are available for studying
the biology of sarcoma cancer-initiating cells in vitro. We
have developed an in vitro model for sarcoma based on
telomerised human stromal cells [7]. In long term cultures,
these cells acquired a transformed phenotype [2, 8]. Histo-
logical analysis of the tumour formed in immune deficient
mice revealed a sarcoma phenotype [8, 9]. Employing this
cell model, our aim was to identify RTKs activated in stromal
cancer stem cells and investigate if chemoresistance can be
overcome by a simultaneous targeting of relevant RTKs.
2. Materials and Methods
2.1. Tumour Model and Cell Culture. We used a cell model
for sarcoma stem cell that has been established from a human
bone marrow stromal (mesenchymal) stem cell (hMSC). The
parental hMSC was immortalized by retroviral transduction
of human telomerase reverse transcriptase (hTERT) gene and
named hMSC-TERT [7, 10]. The parental nontumorigenic
hMSC-TERT4 has the ability of extensive proliferation in
addition to its capacity for multilineage differentiation but it
does not have the ability to form tumours [8]. The hMSC-
TERT cells spontaneously acquired the transformed pheno-
type during long term culture in vitro as evidenced by the
ability to form tumours in nudemice [2]. A clonal population
derived from the parental hMSC-TERT designated hMSC-
TERT20-CE8 was chosen [8]. The derivation and characteri-
zation of nontransformed cell line hMSC-TERT and the clone
hMSC-TERT20-CE8 have been described previously. These
cells have the potential to differentiate to specific lineages of
mesenchymal tissue under well-defined culturing conditions
[2, 8]. The transformed cell lines form sarcoma-like tumours
when implanted in immune deficient mice in vivo [2, 9].
Both cell lines were passaged in minimal essential media
(MEM) (Gibco, Life Technologies) supplemented with 1% L-
glutamine (Gibco, Life Technologies), 10% fetal bovine serum
(Gibco, Life Technologies), and 1% Penicillin-Streptomycin
(Gibco, Life Technologies). Cells were incubated in 5% CO
2
humidified atmosphere at 37∘C.
2.2. Cell Treatments and Viability Assay. To assess cell viabil-
ity, we used CellTiter 96 Aqueous Nonradioactive Cell Pro-
liferation Assay (MTS) (Promega) following manufacturer’s
instructions. Erlotinib, afatinib, and dasatinib were pur-
chased as 10mM stocks dissolved in DMSO (Selleckchem).
Doxorubicin (Accord) 2mg/mL was diluted in 10mL NaCl
9mg/mL.
Adherent cells were detached using Trypsin-EDTA
(0.25%, Gibco, Life Technologies) for 2min. After detach-
ment, 10mL MEM media were added and cells were cen-
trifuged at 1800 RPM for 3min. Cells were resuspended in
MEM media and plated in 96-well plates at a concentration
of 5000 cells/well. After 24 hours of incubation, the cells were
treated with different concentrations of TKIs (0.01–5 𝜇M),
doxorubicin (5–100 nM), or DMSO alone for 72 h. After the
treatment for the indicated time, MTS was added to each
well and incubated at 37∘C for 1 to 4 h. The MTS containing
medium was transferred to a new 96-well plate and the
absorbance at 492 nm was measured (Background 690 nm).
MTS control MEM media without cells were added to each
plate. Results were expressed as fold changes compared to the
untreated control.
2.3. Receptor Tyrosine Kinase (RTK) Activation. Cellular acti-
vation of forty-nine different humanRTKswas assessed using
the Human Phospho-Receptor Tyrosine Kinase Array Kit
(R&D Systems) following manufacturer’s instructions.
2.4. RNA Extraction and qPCR. The cells were harvested
using a cell scraper, centrifuged at 2000 rpm for 5min, and
resuspended in Buffer RLT (Qiagen). RNA was extracted
using the RNeasy Mini Kit on the QIAcube platform (Qia-
gen). RNAwas eluted in RNase free water for further analysis.
The amount of purified RNAwas quantified by the Nanodrop
2000c (Thermo Scientific).
Complementary DNA (cDNA) was synthesized from
100 ng total RNA using 50U MuLV Reverse Transcriptase
(Applied Biosystems), 1X PCR buffer (Applied Biosystems),
6.3mMMgCl
2
(Applied Biosystems), 1mM of each of dATP,
dTTP, dGTP, and dCTP (VWR), 2.5 𝜇MOligod (T
16
) Primer
(DNA Technology), and 20U RNase inhibitor (Applied
Biosystems). The final reaction was diluted to a total volume
of 20𝜇L.
Quantitative PCR (qPCR) was performed in a 10𝜇L reac-
tion volume containing 5 𝜇L LightCycler 480 SYBR Green
I Master (Roche Diagnostics, Mannheim), 3𝜇L RNase free
H
2
O, 0.5 𝜇L forward primer (5 pm/𝜇L), 0.5 𝜇L reverse primer
(5 pm/𝜇L), and 1 𝜇L cDNA.The PCR reaction was as follows:
95∘C for 10min, 50 cycles of 95∘C for 10 sec, specific annealing
temperature for 20 sec, and 72∘C for 5 sec. Melting curves
were produced with the following profile: 99∘C for 1 sec,
59∘C for 15 sec, and a final warming to 95∘C. Lastly, samples
were cooled to 40∘C. Samples were loaded in triplicate along
with negative controls. Crossing point (CP) values with
a standard deviation above 0.5 between replicate samples
were dismissed. Negative controls consisted of no template
control and were tested on each plate. Primer sequences and
annealing temperatures are given in supplementary Table 1.
The mRNA expression level for each of the 4 receptors
(EGFR and HER2–4) and ligands (amphiregulin HB-EGF
and epiregulin) were determined using calibration curves
prepared by serial dilution of RNA from cell lines containing
the mRNA of interest. The expression levels were normalized
to the expression of the reference gene beta-2 microglobulin
(B2M).
2.5. Western Blotting. Cells were collected in scraping buffer
(4mM iodoacetic acid, 1mM Na-Orthovanadate, 1𝜇g/mL
of each inhibitor Pepstatin, Chymostatin, Leupeptin, and
Aprotinin), centrifuged, resuspended in RIPA buffer (50 nM
Tris-HCL pH7.4, 150 nM NaCl, 1% NP-40, 0.25% Na-
deoxycholate, 1mM PMSF, 1mM Orthovanadate, 1 𝜇g/mL
of each inhibitor Aprotinin, Chymostatin, Leupeptin, and
Pepstatin), and homogenized with gentle vortexing. Samples
were centrifuged at 14,000 g for 15min at 4∘C. The protein
concentration was determined using the Nanodrop 2000c
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(Thermo Scientific). 250 𝜇g proteins were resolved on 4–
12% Bis-Tris gels (NuPage, Life Technologies) and trans-
ferred to a PVDF membrane (IBlot, Life Technologies).
Membranes were blocked using 1X TBST with 5% nonfat
dry milk (EGFR, p-EGFR, Akt, Src, p-Scr, MAPK, and
p-MAPK) or 5% BSA (p-Akt). For protein detection, the
following primary antibodies and dilutions were used: anti-
EGFR (Abcam, 1 : 1000), anti-EGFR phospho-Tyr1173 (LSBio,
1 : 500), anti-Akt (Cell Signalling, 1 : 500), anti-Akt phospho-
Ser473 (Cell Signalling, 1 : 500), anti-Src (Cell Signalling,
1 : 1000), anti-Src phospho-Tyr416 (Cell Signalling, 1 : 1000),
anti-MAPK (Cell Signalling, 1 : 1000), anti-MAPK phospho-
Thr202/Tyr204 (Cell Signalling, 1 : 1000), and anti-Histone
H3 (Cell Signalling, 1 : 2000). Antibodies were diluted in
either 1X TBST with 5% nonfat dry milk (EGFR, p-EGFR,
Akt, and H3) or 5% BSA (p-Akt, Src, and p-Src). Goat anti-
rabbit secondary antibodies were diluted in 1X TBST with
5% nonfat dry milk (DAKO; EGFR, p-EGFR, Akt, MAPK,
and p-MAPK; 1 : 4000) (Cell Signalling; Src, p-Src, and p-
Akt; 1 : 5000). SuperSignal West Dura Chemiluminescent
Substrate (ECL) was used for detection of protein (Thermo
Scientific).
2.6. Statistics. The MTS data were analysed by first sub-
tracting the mean background absorbance from each mea-
surement after which the fold changes in cell viability were
calculated by the mean absorbance divided by the mean
absorbance in the control cell group (not treated) separated
by treatment group and cell type. This was done for each
experiment separately. Consistency between the experiments
was tested by logistic regression analysis and the fold change
values were pooled. All cell lines were investigated as triplets
or sextuplet. MTS data were reported as mean values with
95% confidence interval for direct comparison and differ-
ences in treatment were tested by linear regression.
For each experiment, mean mRNA expression was cal-
culated for the specific receptors and ligands were examined
and reported with 95% confidence interval.ThemeanmRNA
expression level was calculated after normalization to a
reference gene. Kruskal-Wallis equality-of-populations rank
test was used to compare different mRNA expression ratios.
Two sided 𝑝 < 0.05 was regarded as significant.
TheWestern blot and themembrane data were quantified
using Image studio Lite v5. The relative density of each band
or sport was calculated by using either the control, nontreated
group or the control spot as standards. For the statistical
analysis STATA (version 13) was used.
3. Results
3.1. Growth and Sensitivity to Chemotherapy. The growth of
the nontumorigenic hMSC-TERT4 and transformed clonal
cell linehMSC-TERT20-CE8 is shown in Figure 1(a). hMSC-
TERT20-CE8 had a higher growth rate compared to the
nontumorigenic hMSC-TERT4. Cell viability analysis shows
that the nontumorigenic hMSC-TERT4 was more sensi-
tive to doxorubicin treatment than hMSC-TERT20-CE8
(Figure 1(b)). Doxorubicin treatment led to decreased cell
Table 1: The mean mRNA expression ratio of HER1, HER2, HER3,
and HER4 receptors for the EGF system and the ligands AR,
EPI, and HB for the parental cell line hMSC-TERT4 and the
derived clonal cell line hMSC-TERT20-CE8 with the ability to form
sarcoma-like tumours inmice. All expressions levels are normalized
to reference gene B2M.The numbers in bold represent the gene that
exhibits significant changes when comparing hMSC-TERT20-CE8
with the parental cell line hMSC-TERT4.
Gene
Mean expression ratio (95% CI)
hMSC-TERT4 hMSC-TERT20-CE8
𝑛 Mean 95% CI 𝑛 Mean 95% CI
HER1 6 3.11 (2.05; 4.17) 9 2.58 (2.12; 3.04)
HER2 6 4.59 (3.65; 5.53) 9 0.93 (0.66; 1.19)
HER3 9 0.76 (0.63; 0.88) 12 0.43 (0.32; 0.54)
HER4 6 0.10 (0.00; 0.19) 9 0.03 (0.01; 0.05)
AR 6 0.65 (0.43; 0.86) 9 40.09 (31.09; 49.01)
EPI 6 0.06 (0.00; 0.12) 9 28.64 (17.28; 39.99)
HB 6 6.65 (3.76; 9.54) 9 21.52 (13.27; 29.77)
viability particularly at a dose concentration between 0 and
10 nM.
3.2. Pattern of Activated Receptor Tyrosine Kinases. We
employed the RTK array to investigate the RTKs activated
in the cell lines. The array detects changes in a panel of
49 RTKs known to be involved in cancer (Figure 2). For
both cell lines, EGFR showed a pronounced activation.
The MET receptor activity was reduced in hMSC-TERT20-
CE8 compared to hMSC-TERT4. Additionally, PDGFR𝛼was
present in hMSC-TERT4 but with a lower intensity than
EGFR.TheAXL expression was the same in the two cell lines.
For quantification of spots, see supplementary Figure 2.
3.3. mRNA Expression of EGF System Receptors and Ligands.
To determine themolecular mechanisms of EGFR activation,
mRNA expression of the receptors and ligands from the
EGF system was determined (Table 1). No difference in
expression of EGFR mRNA was found between hMSC-
TERT4 and hMSC-TERT20-CE8. The tumorigenic hMSC-
TERT20-CE8 showed significantly lower expression of HER2
andHER3mRNA and a significantly higher expression of the
ligands amphiregulin (AR), epiregulin (EPI), and Heparin-
binding EGF like growth factor (HB-EGF) compared to the
nontumorigenic hMSC-TERT4 (Table 1).
3.4. TKI Treatment of the Cells Lines. Erlotinib targeting
EGFR and afatinib targeting EGFR, HER2, and HER4 were
used for testing sensitivity to EGFR system inhibition. The
fold change in cell viability, for the hMSC-TERT4 and hMSC-
TERT20-CE8 treated with the TKIs, is shown in Figure 3.
Erlotinib treatment, at a concentration of 5𝜇M, decreased
cell viability of hMSC-TERT4 to 0.65 (95% CI: 0.63–0.68)
and that of hMSC-TERT20-CE8 to 0.88 (95%CI: 0.783–0.96).
A significant reduction in cell viability was observed in the
hMSC-TERT4 cells treated with erlotinib compared to both
the nontreated hMSC-TERT4 (𝑝 < 0.001) and the erlotinib
treated hMSC-TERT20-CE8 cell line (𝑝 < 0.001).
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Figure 1: The growth and the sensitivity to doxorubicin of a transformed human mesenchymal (stromal) stem cell line hMSC-TERT4
(solid line) and a derived clonal cell line with the ability to form sarcoma-like tumours in mice hMSC-TERT20-CE8 (CE8, dashed line).
The doxorubicin experiments were performed twice with 9 replicates (for the two highest doxorubicin concentrations the experiment was
performed once and with 6 replicates). The mean fold change in growth is shown with 95% confidence interval.
HER3
PDGF R𝛼
EGFR
MET
(a) (b)
Figure 2: Human Phospho-Receptor Tyrosine Kinase (RTK) Array blots. The activated RTKs are determined in human telomerised stromal
stem cell lines (hMSC-TERT). (a) hMSC-TERT4, nontumorigenic. (b) hMSC-TERT20-CE8 a clonal cell line with the ability to form sarcoma-
like tumours in mice. The activated tyrosine kinases are represented by black dots on the membranes. For quantification data of the
membranes, see supplementary Figure 2 in Supplementary Material available online at http://dx.doi.org/10.1155/2016/9601493.
Afatinib treatment, at a concentration of 5 𝜇M, also
showed a change in cell viability of hMSC-TERT4 to 0.34
(95% CI: 0.32; 0.36) and hMSC-TERT20-CE8 to 1.05 (95%
CI: 0.87; 1.23). For the hMSC-TERT4 cells, this reduction
was significant compared to both nontreated hMSC-TERT4
cells (𝑝 < 0.001) and afatinib treated hMSC-TERT20-CE8
cells (𝑝 < 0.001). No significant reduction in cell viability
was observed in the afatinib treated hMSC-TERT20-CE8 cells
compared to nontreated cells (𝑝 = 0.28).
Combined treatment with the EGFR inhibitors and dox-
orubicin resulted in no additional effects on hMSC-TERT20-
CE8 (Figure 4). These results suggest that direct targeting of
EGFR does not reverse the doxorubicin resistance.
We then tested the effect of blocking the downstream
tyrosine kinase SRC on the doxorubicin resistance pheno-
type. Dasatinib is a combined SRC and DDR2 inhibitor.
Dasatinib treatment, at a concentration of 5 𝜇M, showed a
marked reduction in cell viability of hMSC-TERT4 to 0.28
(95%CI: 0.25; 0.31) and hMSC-TERT20-CE8 to 0.74 (95%CI:
0.77; 0.80).These resultswere significantwhen comparing the
two treated cells lines (𝑝 < 0.001) and when compared to
the nontreated cells (𝑝 < 0.001) for each cell line separately.
Dasatinib resulted in inhibition of the phosphorylated SRC
andAKT pathway, while theMAKP pathway was not affected
(Figure 5). For quantitative data on the intensities in the
Western blot, see supplementary Figure 3.
The combined treatment with dasatinib (5 𝜇M) and
doxorubicin (25 nM) significantly decreased cell viability of
hMSC-TERT20-CE8 compared to treatment with doxoru-
bicin alone: 0.50 (95% CI: 0.48; 0.52) versus 0.78 (95% CI:
0.69; 0.90), respectively, 𝑝 = 0.002. The same was true using
a doxorubicin concentration of 50 nM (𝑝 = 0.009).
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Figure 3: Cell viability was determined by non-Radioactive Cell Proliferation Assay (MTS) for erlotinib (concentrations: 0.01–5𝜇M), afatinib
(concentrations: 0.01–5𝜇M), and dasatinib (concentrations: 0.01–5𝜇M) in hMSC-TERT4 (solid line) and hMSC-TERT20-CE8 (dashed lines).
The results are presented as fold changes compared to the nontreated cells.TheMTS assays were performed twice with total of 9 replicates for
the erlotinib treated cells. TheMTS assay was performed once with 6 replicates for the afatinib treated cells. TheMTS assays were performed
two or three times with at least a total of 12 replicates for the dasatinib treated cells. The cell viability is presented as mean value with 95%
confidence interval for direct comparison. The cells were treated for 72 hours.
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Figure 4: Cell viability expressed as mean fold changes and 95%
confidence interval after treatment of hMSC-TERT20-CE8 which
are clonal cells lines derived from stromal stem cell line and with
the ability to form sarcoma-like tumours in mice. (1) Control,
no treatment. (2) Doxorubicin 25 nM. (3) Doxorubicin 25 nM
+ dasatinib 5 𝜇M. (4) Doxorubicin 25 nM + erlotinib 5 𝜇M. (5)
Doxorubicin 50 nM. (6) Doxorubicin 50 nM + dasatinib 5 𝜇M. (7)
Doxorubicin 50 nM + erlotinib 5 𝜇M. (8) Doxorubicin 50 nM +
afatinib 5𝜇M. (9) Dasatinib 5 𝜇M. (10) Erlotinib 5𝜇M. (11) Afatinib
5 𝜇M. The experiments were performed twice with at least a total
of 6 replicates of each cell line. Significant results compared to
the nontreated cells are marked with ∗ whereas significant results
compared to the corresponding doxorubicin treatment are marked
with nontreatment ∗∗.
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Figure 5: Western blot analysis of total and activation of the EGFR,
Src, Akt, and MAPK in hMSC-TERT4 and hMSC-TERT20-CE8
which is clonal cell line derived from mesenchymal (stromal) stem
cells and with the ability to form sarcoma-like tumours in mice.
The cell lines were treated for 72 h with either vehicle, erlotinib
5 𝜇M, or dasatinib 5𝜇M. t, total; p, phosphorylated. Histone H3 was
used as loading control. For quantification data, see supplementary
Figure 3.
4. Discussion
Our results demonstrated that combining dasatinib and
doxorubicin decreases cell viability of a cell line less sensitive
to doxorubicin treatment and that targeting EGFR may not
be a future treatment strategy for sarcoma patient.
Recent studies have shown that increased expression of
EGFR is associated with high-grade sarcoma [11] and poor
prognosis [12] and that treatment with EGFR inhibitors can
sensitize sarcoma cell lines to chemotherapy in vitro and in
vivo [13]. However, a phase II clinical trial treating sarcoma
patients resistant to chemotherapy with gefitinib, as single
agent therapy, failed in increasing time to tumour progression
[14].
The resistance to oncological treatment may reside in a
small group of tumour initiating stem cells. Our study used a
model of nontransformed and transformed stromal stem cell
lines to test the sensitivity of sarcoma tumour initiating stem
cells to tyrosine kinase inhibitors. The results of our exper-
iments are in agreement with the clinical results since they
showed that the EGFR activated signaling in nontransformed
and transformed stromal cell lines did not result in increased
sensitivity to treatment with the EGFR inhibitors erlotinib
and afatinib. Furthermore, a combined treatment of EGFR
inhibitors and doxorubicin did not increase the efficacy of
doxorubicin in killing transformed stromal stem cells. The
employed erlotinib concentration has previously reduced cell
viability in other cancer cell lines [15].Therefore, even though
the reduction in cell viability, comparing nontreated and
erlotinib treated hMSC-TERT20-CE8, was significant (𝑝 =
0.003), the tumorigenic cell line, in this study, is considered
relatively resistant to erlotinib.
The erlotinib concentration of 5𝜇M only reduced acti-
vation of EGFR but did not block the activation of EGFR
completely. Interestingly, this concentration has been demon-
strated to completely inhibit EGFR phosphorylation in other
cancer models [16, 17]. This suggests that EGFR in stromal
stem cells are cross-activated by other receptors that are
refractory to erlotinib inhibition. Our findings correspond
to results from a previous study where coactivation of EGFR
and an opioid receptor in non-small cell lung cancer has
been observed [18]. We have tested higher concentration of
erlotinib (supplementary Figure 1). At these higher concen-
trations, a further reduction in cell viabilitywas observed. Yet,
these erlotinib concentrations are not clinically relevant [19].
Gene expression profiling of leiomyosarcomas and undif-
ferentiated pleomorphic sarcomas has suggested that SRC
can be employed as a diagnostic marker [20]. SRC is
activated through EGFR system or the discoidin domain
receptor 2 (DDR2) [21]. DDR2 is a tyrosine kinase (RTK)
expressedmainly in stromal or fibroblastic cells. An increased
expression and activation of DDR2 in breast cancer cells are
associated with a malignant phenotype and the expression of
DDR2 is increased as a result of hypoxia [22].
Our study shows that, by inhibiting a downstream RTK
of EGFR, using dasatinib, which among other inhibits SRC
and DDR2, only reduces cancer cell viability slightly when
given alone but significantly decreases cells’ viability of the
otherwise doxorubicin stem cell line when combined with
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doxorubicin. Dasatinib inhibits PDGFR, DDR2, and the SRC
family. Our results are supported by the work of van Oost-
erwijk et al. showing that dasatinib acts synergistically with
doxorubicin in inhibiting cell viability of chondrosarcoma
cell lines [23]. It has previously been shown in breast carci-
noma cell lines that inhibition of SRC family kinases prevents
the phosphorylation of MAPK induced by stimulation of
EGFR [17]. However, our results show that inhibition of
SRC did not decrease the phosphorylated state of MAPK,
whereas the phosphorylation of AKTwas lowered in both the
transformed and the nontransformed cell lines.
The transformed cell line was responsive to the combined
treatment with doxorubicin and dasatinib. Coactivation of
RTKs was tested by using p-AKT protein as a molecular
surrogate for downstream RTK signaling. We could confirm
that single agent treatment with erlotinib could not effectively
block phosphorylation of the AKT protein.
It is believed that most of the tumour volume is com-
posed of descendants from cancer-initiating cells [24]. These
heterogeneous clusters of various tumour cells may have
different molecular pathways to overcome treatment effects
and will therefore have different sensitivities to different
treatments. Targeting the downstream pathway of SRC is
only one of various possible mechanisms and is not expected
therefore to be a universal mechanism to sensitize sarcomas
to doxorubicin. Furthermore, dasatinib is not a specific
inhibitor of SRC. Indeed another hMSC-TERT derived
tumorigenic cell line (BD11) was not responsive to dasatinib
(data not shown) and the nontransformed cell line hMSC-
TERT4 was even more sensitive to dasatinib than hMSC-
TERT-CE8.The activation of critical pathways for survival of
mesenchymal cancer cells may be determined by the sum of
multiple inputs andmultiple RTKs.These RTKsmay be active
simultaneously or sequentially to maintain cell survival [5].
Therefore, a combination of different TKIs, a combination of
TKIs and chemotherapy, or targeting downstream TKIs may
be required.
Our study suggest that combining dasatinib and doxoru-
bicin results in lower cell viability than either treatment alone.
Therefore, this may be a treatment modality to be considered
for metastatic STS patients. We also propose that different
resistant cell lines acquire different resistant mechanisms
even though they originated from the same parental stem cell.
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